GGrantIndex
Sort

64,565 grants matching drug discovery

Mycobacterium tuberculosis environmental signal integration: single cell in vivo understanding of its influence on infection heterogeneity and treatment efficacy

$620,485
Shumin Tan · Tufts University Boston · R01 · FY2019 · AI

Advancing Knowledge Discovery for Postoperative Pain Management

$620,483
Tina Hernandez-Boussard · Stanford University · R01 · FY2023 · LM

NIDA Epidemiology Training Program

$620,403
C Debra Furr-Holden · Johns Hopkins University · T32 · FY2013 · DA

Rational generation of high-performance recombinant antibodies to post-translational modifications

$620,370
Takamitsu Hattori · New York University School Of Medicine · R21 · FY2020 · CA

Preclinical optimization of a parasiticidal drug for cryptosporidiosis

$620,271
Christopher D Huston · University Of Vermont & St Agric College · R01 · FY2021 · AI

Preclinical optimization of a parasiticidal drug for cryptosporidiosis

$620,271
Christopher D Huston · University Of Vermont & St Agric College · R01 · FY2020 · AI

Discovery of New Anti-Inflammatory Agents to Treat COPD

$620,269
Mikell Paige · George Mason University · R01 · FY2016 · HL

Modeling Cardiovascular Risks of Air Pollutants with Human Induced Pluripotent Stem Cell-Derived Cardiovascular-Associated Cells (Project 3) for the Air pollution disrupts Inflammasome Regulation in

$620,255
Joseph C Wu · Stanford University · P01 · FY2021 · HL

Characterization of novel insulin resistance genes by gene editing, high-throughput phenotyping and in vivo studies

$620,254
Joshua Wiley Knowles · Stanford University · R01 · FY2023 · DK

Therapeutic approaches for LKB1-deficient non-small cell lung cancer

$620,252
John V. Heymach · University Of Tx Md Anderson Can Ctr · R01 · FY2016 · CA

Modeling Cardiovascular Risks of Air Pollutants with Human Induced Pluripotent Stem Cell-Derived Cardiovascular-Associated Cells (Project 3) for the Air pollution disrupts Inflammasome Regulation in

$620,156
Joseph C Wu · Stanford University · P01 · FY2022 · HL

Small-molecule STAT3 degraders

$620,148
Shaomeng Wang · University Of Michigan At Ann Arbor · R01 · FY2021 · CA

The hippocampal dentate gyrus in aging and Alzheimer's disease: boosting transcription of retinoic acid-sensitive genes through vitamin A supplementation and HDAC inhibition

$620,095
John Joshua Lawrence · Texas Tech University Health Scis Center · R01 · FY2025 · AG

Decoding Methylation Mediated Epigenomic Contributions to Male Osteoporosis

$620,035
Hong-Wen Deng · Tulane University Of Louisiana · R01 · FY2020 · AR

CETP and HDL Function in Cardiovascular Diseases

$620,011
Yuqing E Chen · University Of Michigan At Ann Arbor · R01 · FY2016 · HL

Genetics and Molecular Biology Parkinsonism

$620,000
Dennis William Dickson · Mayo Clinic Jacksonville · P50 · FY2011 · NS

A Structural Systems Biology Approach to Drug Discovery

$620,000
Rommie E Amaro · University Of California, San Diego · DP2 · FY2015 · OD

Structural Basis of Signal Instigation Through Family C GPCRs

$619,967
Georgios Skiniotis · Stanford University · R01 · FY2022 · NS

SBIR Phase II: Development of Novel Dendrimer-based Technologies for Phosphorylation Analyses

$619,948
Anton Iliuk · Tymora Analytical Operations, Llc · · FY2013 · TIP

Using patient-derived models to understand drug responses in SCLC

$619,923
Nicholas J Dyson · Massachusetts General Hospital · U01 · FY2020 · CA

Using patient-derived models to understand drug responses in SCLC

$619,923
Nicholas J Dyson · Massachusetts General Hospital · U01 · FY2018 · CA

Targeting RAGE/DIAPH1: Novel Therapeutic Strategy for Diabetic Complications

$619,879
Ann Marie Schmidt · New York University School Of Medicine · R01 · FY2022 · DK

SPORE IN PROSTATE CANCER

$619,876
Johns Hopkins University · P50 · FY2003 · CA

Frataxin deficiency as a cause of endothelial senescence in multiple subtypes of pulmonary hypertension

$619,875
Stephen Y Chan · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · HL

A CETR-based partnership accelerator for rapid drug development targeting SARS-CoV-2 and pan-CoVs

$619,850
David S Perlin · Hackensack University Medical Center · U19 · FY2020 · AI